Send to

Choose Destination
J Hepatocell Carcinoma. 2016 Jul 25;3:25-9. doi: 10.2147/JHC.S50359. eCollection 2016.

Transarterial radioembolization for hepatocellular carcinoma: a review.

Author information

Department of Gastroenterology, Cisanello Hospital, Pisa.
Endocrinology and Metabolic Diseases, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Rome.
Department of Engineering and Architecture, University of Trieste, Trieste.
Department of Surgical Sciences and Integrated Diagnostics, School of Medicine, Genova University, Genoa.
Section of Gastroenterology, DIBIMIS, University of Palermo, Palermo, Italy.


Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is the second cause of death due to malignancy in the world. The treatment of HCC is complex and includes potentially curative and palliative approaches. However, both curative and palliative treatments for HCC are often associated with a not-completely favorable safety/efficacy ratio. Therefore, other treatment options appear necessary in clinical practice. Transarterial radioembolization has shown a promising efficacy in terms of disease control and is associated with a good safety profile. This review discusses the use of transarterial radioembolization in HCC, with a focus on the clinical aspects of this therapeutic strategy.


hepatocellular carcinoma; transarterial radioembolization

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center